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Histopathologic evaluation of placentas after diagnosis
of maternal severe acute respiratory syndrome
coronavirus 2 infection
Moti Gulersen, MD, MSc; Lakha Prasannan, MD; Hima Tam Tam, MD; Christine N. Metz, PhD; Burton Rochelson, MD;
Natalie Meirowitz, MD; Weiwei Shan, PhD; Morris Edelman, MD; Karmaine A. Millington, MD

BACKGROUND: The impact of maternal severe acute respiratory
syndrome coronavirus 2 infection on placental histopathology is not well
known.
OBJECTIVE: To determine if any significant placental histopathologic
changes occur after the diagnosis of severe acute respiratory syndrome
coronavirus 2 infection during pregnancy and whether these changes are
correlated with the presence or absence of symptoms associated with the
infection.
STUDY DESIGN: A retrospective cohort study of women diagnosed as
having severe acute respiratory syndrome coronavirus 2 infection who
delivered at a single center from April 9, 2020 to April 27, 2020, and had
placental specimens reviewed by the Department of Pathology. Women
with singleton gestations and laboratory-confirmed severe acute respiratory syndrome coronavirus 2 infection were eligible for inclusion. Historical
controls selected from a cohort of women who delivered 6 months before
the study period were matched in a 1:1 fashion by weeks of gestation at
delivery. Histopathologic characteristics were evaluated in each placenta,
and the incidence of these findings was compared between placentas of
those who received a diagnosis of maternal severe acute respiratory
syndrome coronavirus 2 infection and historical controls, and between
placentas from patients with or without typical symptoms related to the
infection. Statistical analyses included the use of Wilcoxon rank-sum test
and Fisher’s exact test for the comparison of categorical and continuous
variables. Statistical significance was defined as a P value of <.05.
RESULTS: A total of 50 placentas after the diagnosis of maternal
severe acute respiratory syndrome coronavirus 2 infection and 50

Introduction
Since the World Health Organization
declared the outbreak of the novel coronavirus (severe acute respiratory distress
syndrome coronavirus 2 [SARS-CoV-2]) a
global pandemic, there have been
approximately 7 million conﬁrmed infections and 400,000 deaths worldwide.1
Contemporaneous with the rapid rate of
increase in infections, rigorous research
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historical controls were analyzed. Among the placentas from patients
diagnosed with severe acute respiratory syndrome coronavirus 2
infection, 3 (6%) were preterm (33 3/7, 34 6/7, and 36 6/7 weeks
of gestation), 16 (32%) were from patients with typical symptoms
related to the infection, and 34 (68%) were from patients without
typical symptoms related to the infection. All patients had received a
diagnosis of severe acute respiratory syndrome coronavirus 2 infection
in the third trimester. Decidual vasculopathy was not visualized in any
of the placentas from patients diagnosed as having severe acute
respiratory syndrome coronavirus 2 infection. There was no statistically significant difference in placental histopathologic characteristics
between the groups. Severe acute respiratory syndrome coronavirus 2
test results for all neonates at 24 hours of life were negative.
CONCLUSION: Based on the results of this study, there are no significant placental histopathologic changes that occur after the diagnosis of
severe acute respiratory syndrome coronavirus 2 infection in women
during the third trimester of pregnancy compared with a gestational
ageematched historical control group. Similar incidences of histopathologic findings were also discovered when comparing placentas from patients with severe acute respiratory syndrome coronavirus 2 infection with
or without the presence of symptoms typically related to the infection.
Key words: coronavirus, coronavirus disease 2019, decidual vascul-

opathy, fetal vascular malperfusion, histopathology, maternal vascular
malperfusion, placental pathology, thrombosis, thrombotic vasculopathy,
thrombus

efforts exploring the impact of this novel
virus in pregnancy have been initiated.
Several adverse pregnancy outcomes in
women with SARS-CoV-2 infection have
been reported thus far, including miscarriage,2,3 intrauterine fetal demise,4 preeclampsia,5,6
preterm
delivery,7e9
7e10
maternal critical illness
and death,4
11,12
and neonatal death.
Evidence
regarding the occurrence of antepartum or
peripartum vertical transmission has been
conﬂicting to date.13e17
The placenta represents a highly
specialized organ that is crucial for
maintaining an optimal environment for
fetal development.18,19 Placental evaluation after delivery provides useful information such as the identiﬁcation of
disease processes in the mother or infant

that require attention or diagnoses that
provide a speciﬁc explanation for an
adverse outcome.20 Characteristic histopathologic ﬁndings in placentas from
mothers with viral infections have been
reported.21e24 However, reports on
placental evaluation in women with
SARS-CoV-2 infection have been limited
to a few case series,25e28 and the association between infection and abnormal
placental ﬁndings are not well known.
Therefore, the objective of this study was
to determine if any signiﬁcant placental
histopathologic changes occur after the
diagnosis of SARS-CoV-2 infection in
pregnancy and whether these changes
are correlated with the presence or
absence of symptoms typically related to
the infection.
NOVEMBER 2020 AJOG MFM
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Why was this study conducted?
The association between maternal severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) infection and placental histopathology is not well known. This
study aimed to determine if any signiﬁcant placental histopathologic changes
occur after the diagnosis of the SARS-CoV-2 infection during pregnancy and
whether these changes are correlated with the presence or absence of symptoms
typically related to the infection.
Key ﬁndings
Our study did not reveal signiﬁcant placental histopathologic changes that occur
after the diagnosis of SARS-CoV-2 infection in women during the third trimester
of pregnancy compared with a gestational ageematched historical control group.
There was no difference in the placental histopathologic ﬁndings when placentas
from the patients were compared after the diagnosis of SARS-CoV-2 infection
with or without the presence of symptoms typically related to the infection.
What does this add to what is known?
The results of this study add to the limited existing literature regarding placental
histopathologic changes associated with SARS-CoV-2 infection and suggest that
pregnancy with maternal SARS-CoV-2 infection may be managed based on the
clinical ﬁndings alone, whereas ﬁndings from placental pathology warranting
increased or different surveillance were not indicated.

Methods
This was a retrospective cohort study
with historical controls. Cases included
placentas from women who were diagnosed as having SARS-CoV-2 infection
and delivered at a single center (Long
Island Jewish Medical Center, Northwell
Health, Queens, NY) from April 9, 2020
to April 27, 2020 (during the peak of the
pandemic in New York). The Northwell
Health Institutional Review Board
approved this study as minimal-risk
research using data collected for
routine clinical practice and waived the
requirement for informed consent.
Women with singleton gestations who
had received a laboratory-conﬁrmed
diagnosis of SARS-CoV-2 infection
during their pregnancy were eligible for
inclusion. The diagnosis of SARS-CoV-2
infection was conﬁrmed using a qualitative real-time polymerase chain reaction (PCR) on maternal nasopharyngeal
swab specimens. Before the study
period, universal testing for SARS-CoV2 infection had been implemented for all
obstetrical patients admitted to labor
and delivery. After delivery, the placentas
were submitted to the Department of
2 AJOG MFM NOVEMBER 2020

Pathology for evaluation. Placentas from
women with high clinical suspicion for
placenta accreta diagnosed during the
antepartum period on either ultrasound
or magnetic resonance imaging were
excluded. Placental specimens from
cases with accreta had a morbidly
adherent uterus. Therefore, several gross
examination characteristics, such as
placental weight, could not be obtained,
and standardized sampling of each
placenta for the histologic evaluation
would not be consistent with that of
other placentas in the study.
Historical controls were selected from
a cohort of women who had placentas
submitted to the Department of Pathology (including specimens obtained
from delivery at North Shore University
Hospital, Northwell Health) during
November 2019—at least 3 months
before the ﬁrst reported case of SARSCoV-2 infection in New York. The decision for pathologic examination at that
time was at the discretion of the delivery
physician. However, the suggested
criteria provided by the Department of
Pathology were generally consistent with
the College of American Pathologists

guidelines.29 Historical controls were
used because placentas from patients
who received negative test results for
SARS-CoV-2 infection during the study
period may not have represented an
appropriate control group owing to the
reported high false-negative rates.30
Controls were matched in a 1:1 fashion
by weeks of gestation at delivery. Gestational age at delivery was selected as the
matching variable given its signiﬁcance
as a possible confounder, because there is
a direct correlation of placental development with advancing gestation.18,19
Placentas were routinely transported
to the Department of Pathology within
24 hours of delivery. All placentas were
examined according to a standardized
protocol. This included storage at 4oC
after delivery, ﬁxation in formalin
(added within 2 hours of specimen
receipt, with a duration of up to 48e72
hours, from women after the diagnosis
of SARS-CoV-2 infection), gross examination with weight and measurements
after ﬁxation, sectioning with processing
in parafﬁn blocks and staining the cut
tissue (4 mm) on glass slides using the
hematoxylin and eosin stain, and, ﬁnally,
microscopic examination of the cut
sections. There were between 5 and 12
microscopic sections examined per
placenta, which represented at least 2
from the umbilical cord, 1 from free
membranes, and 2 full-thickness sections of placental disc including fetal and
maternal surfaces. If visible lesions were
present, the representative samples of
such lesions were obtained and examined. Placentas were not tested for SARSCoV-2 infection. Histopathologic characteristics evaluated for each placenta
included the presence or absence of
maternal vascular malperfusion such as
accelerated villous maturation, decidual
vasculopathy, distal villous hypoplasia,
excessive infarction, and old hemorrhage
in membranes. Additional characteristics evaluated included the presence or
absence of chorionitis, amnionitis, umbilical vasculitis, villitis, intervillous
thrombi, fetal vascular malperfusion,
increased perivillous ﬁbrin, delayed
villous
maturation,
retroplacental
thrombus, chorangiosis, and meconium
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staining. All examinations were reviewed
by an experienced perinatal and pediatric pathology subspecialist (K.A.M.)
who utilized a standardized set of criteria
for sampling and deﬁning placental lesions,31 and was not blinded to the patient’s clinical history or diagnosis of
SARS-CoV-2 infection.
Maternal and neonatal characteristics
collected from each medical record
included maternal age, race or ethnicity,
parity, gestational age at diagnosis of
SARS-CoV-2 infection, presence or
absence of symptoms typically related to
SARS-CoV-2 infection (ie, fever or chills,
cough, dyspnea, myalgias, nausea and
vomiting, diarrhea, headache, anosmia
or ageusia), gestational age at delivery,
the time interval from diagnosis of
infection to delivery, mode of delivery,
neonatal birthweight, and neonatal
SARS-CoV-2 test at 24 hours of life.
Maternal disease severity was further
classiﬁed based on the deﬁned criteria
from the United States National Institutes of Health.32 Mild cases were
deﬁned as those who have symptoms
typically related to SARS-CoV-2 infection, but without dyspnea or abnormal
imaging. Moderate cases were deﬁned as
those who had evidence of lower respiratory disease by clinical assessment or
imaging and a blood oxygen saturation
of >93% on room air. Severe cases were
deﬁned as those with a respiratory rate
30 breaths per minute, blood oxygen
saturation of 93% on room air, partial
pressure of arterial oxygen to fraction of
inspired oxygen of <300 mm Hg, and
lung inﬁltrates of >50%. Critical cases
were deﬁned as those who exhibited
respiratory failure, septic shock, or
multiple organ dysfunction or failure.
A total of 2 comparative analyses
evaluating the histopathologic characteristics of placentas were performed.
The ﬁrst comparison was between placentas from women after the diagnosis of
SARS-CoV-2 infection and gestational
ageematched historical controls. The
second comparison was between placentas from women after the diagnosis of
SARS-CoV-2 infection who had typical
symptoms related to the infection and
those who did not have such typical
symptoms. Statistical analysis included

TABLE 1

Characteristics of the study cohort at baseline
Characteristic
Maternal age (y), median (IQR)

Patients with SARS-CoV-2
infection (n¼50)

Historical controls
(n¼50)

P
value

30 (24.25e33.75)

30 (27.00e33.75) .57

12 (24)

16 (32)

14 (28)

16 (32)

7 (14)

10 (20)

Race or ethnic group, n (%)
Non-Hispanic black
Non-Hispanic white
Asian
Hispanic

9 (18)

2 (4)

Other or multiracial

6 (12)

3 (6)

Unknown

2 (4)

3 (6)

24 (48)

20 (40)

Nulliparous, n (%)
Gestational age at delivery (wk),
median (IQR)

39.3 (38.45e40.10)

.23

.55

39.3 (38.40e40.25) .86

Antepartum or intrapartum
complications, n (%)
Pregestational diabetes

1 (2)

1 (2)

1

Gestational diabetes

1 (2)

7 (14)

.059

Gestational hypertension

3 (6)

1 (2)

.62

0

1 (2)

1

Chronic hypertension
Preeclampsia with severe
features

4 (8)

6 (12)

.74

Preeclampsia without severe
features

1 (2)

1 (2)

1

Fetal growth restriction

2 (4)

5 (10)

.44

Intrahepatic cholestasis of
pregnancy

3 (6)

2 (4)

1

Oligohydramnios

1 (2)

2 (4)

1

Placental abruption

0

1 (2)

1

Intrapartum fever

6 (12)

8 (16)

.77

Vaginal delivery, n (%)

38 (76)

28 (56)

.057

Birthweight (g), median (IQR)

3213 (2771e3435)

3353 (2766e3635)

.44

Data are presented as number (percentage) or median (IQR).
IQR, interquartile range; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Gulersen et al. Placental histopathologic changes after maternal SARS-CoV-2 infection. AJOG MFM 2020.

the use of the Wilcoxon rank-sum test
and Fisher’s exact test for comparison of
categorical and continuous variables.
Statistical signiﬁcance was deﬁned as a P
value of <.05.

Results
During the study period, a total of 52
placentas from singleton gestations
diagnosed as having SARS-CoV-2

infection were submitted to the Department of Pathology. Of note, 2 cases with
placenta accreta were excluded from the
analysis. Therefore, the study cohort
included 50 placentas after the diagnosis
of maternal SARS-CoV-2 infection and
50 placentas as historical controls, which
were further analyzed. Among placentas
from the patients who were diagnosed as
having SARS-CoV-2 infection, 3 (6%)
NOVEMBER 2020 AJOG MFM
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TABLE 2

Comparison of histopathologic characteristics of placentas from women
after diagnosis of SARS-CoV-2 infection and gestational ageematched
historical controls
Patients with SARS-CoV-2
infection (n¼50)

Historical
Controls (n¼50)

P
value

Placental weight
<10th percentile

7 (14)

10 (20)

40 (80)

37 (74)

3 (6)

3 (6)

Accelerated villous
maturation

0

1 (2)

1

Decidual vasculopathy

0

1 (2)

1

Distal villous hypoplasia

2 (4)

1 (2)

1

Excessive infarction

4 (8)

4 (8)

1

Old hemorrhage in
membranes

1 (2)

2 (4)

1

10the90th percentile
>90th percentile

.87

Maternal vascular
malperfusion

Fetal vascular malperfusion

4 (8)

6 (12)

.74

Increased perivillous fibrin

6 (12)

7 (14)

1

Intervillous thrombus

13 (26)

8 (16)

.33

Delayed villous maturation

10 (20)

13 (26)

.64

Villitis

2 (4)

1 (2)

1

Chorionitis

11 (22)

8 (16)

.61

Amnionitis

9 (18)

4 (8)

.23

Umbilical vasculitis

7 (14)

8 (16)

1

Retroplacental thrombus

2 (4)

0

.5

Chorangiosis

3 (6)

1 (2)

.62

Chorangioma

0

1 (2)

1

9 (18)

5 (10)

.39

Meconium staining

Data are presented as number (percentage).
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Gulersen et al. Placental histopathologic changes after maternal SARS-CoV-2 infection. AJOG MFM 2020.

were preterm (33 3/7 weeks, 34 6/7
weeks, and 36 6/7 weeks), 16 (32%) were
from patients who had typical symptoms
related to infection, and 34 (68%) were
from patients who did not have typical
symptoms related to the infection. Disease severity for the 16 cases from patients with symptoms related to SARSCoV-2 infection included 9 with mild
disease, 3 with moderate disease, 2 with
severe disease, and 1 with the critical
disease. All patients had received a
diagnosis of SARS-CoV-2 infection in
the third trimester. There were 2 patients
4 AJOG MFM NOVEMBER 2020

who had recovered from the infection
and had negative SARS-CoV-2 test results at the time of delivery. The results of
SARS-CoV-2 testing by means of PCR
for all neonates at 24 hours of life were
negative.
Maternal age, race or ethnicity, parity,
gestational age at delivery, mode of delivery, neonatal birthweight, and the
number of antepartum or intrapartum
complications were similar between patients with SARS-CoV-2 infection and
historical controls (Table 1). Histopathologic ﬁndings, such as accelerated

villous maturation or decidual vasculopathy, were not visualized in any of the
placentas from patients with SARS-CoV2 infection. There was no statistically
signiﬁcant difference in maternal
vascular malperfusion histopathologic
characteristics, such as distal villous hypoplasia (4% vs 2%), excessive infarction
(8% vs 8%), and old hemorrhage in
membranes (2% vs 4%), between the 2
groups (Table 2). There were also no
statistically signiﬁcant difference in fetal
vascular malperfusion (8% vs 12%),
increased perivillous ﬁbrin (12% vs
14%), intervillous thombi (26% vs
16%), chorangiosis (6% vs 2%), or the
presence of meconium staining (18% vs
10%) between the 2 groups (Table 2).
On subgroup analysis, maternal age,
race or ethnicity, parity, gestational age at
delivery, mode of delivery, neonatal
birthweight, and the number of antepartum or intrapartum complications
were similar between patients with
SARS-CoV-2 infection who had typical
symptoms related to the infection and
those who did not have such typical
symptoms (Table 3). The time interval
from the diagnosis of SARS-CoV-2
infection to delivery was signiﬁcantly
higher among patients who had typical
symptoms related to the SARS-CoV-2
infection than those who did not have
such typical symptoms (12.5 days vs 0.5
days; P<.001). There was no statistically
signiﬁcant difference in maternal
vascular malperfusion histologic characteristics such as distal villous hypoplasia (0% vs 5.9%), excessive infarction
(18.8% vs 2.9%), and old hemorrhage in
membranes (6.2% vs 0%) between the 2
groups (Table 4). There were also no
statistically signiﬁcant differences in fetal
vascular malperfusion (6.2% vs 8.8%),
increased perivillous ﬁbrin (12.5% vs
11.8%), intervillous thombi (37.5% vs
20.6%), chorangiosis (6.2% vs 5.9%), or
the presence of meconium staining (25%
vs 14.7%) between the 2 groups
(Table 4).

Discussion
Principal findings
The results of our study did not indicate
signiﬁcant placental histopathologic
changes that occur after the diagnosis of

Original Research
SARS-CoV-2 infection in women during
the third trimester of pregnancy
compared
with
a
gestational
ageematched historical control group
with a similar incidence of antepartum
or intrapartum complications. Moreover, there was no difference in placental
histopathologic ﬁndings when placentas
from the patients were compared
after the diagnosis of SARS-CoV-2
infection with or without the presence
of symptoms typically related to the
infection.

TABLE 3

Characteristics of patients with symptoms related to SARS-CoV-2 infection
compared with those without such symptoms

Characteristic
Maternal age (y), median (IQR)

Patients with
symptoms related to
SARS-CoV-2 infection
(n¼16)
31 (28.00e34.25)

Patients without
symptoms related
to SARS-CoV-2
infection (n¼34)

P
value

29.5 (24e33)

.19
.46

Race or ethnic group, n (%)
Non-Hispanic black

2 (12.5)

10 (29.4)

Non-Hispanic white

5 (31.25)

9 (26.5)

Asian

2 (12.5)

5 (14.7)

Results

Hispanic

5 (31.25)

4 (11.8)

There is a paucity of data regarding
placental pathology from patients with
SARS-CoV-2 infection. Shanes et al25
recently described histopathologic ﬁndings in placentas of 15 women with
SARS-CoV-2 infection from 34 to 40
weeks of gestation and compared with
either a historical control group of thirdtrimester placentas submitted for suggested clinical indications to the
Department of Pathology for examination or because of a history of melanoma. Compared with all historical
controls, placentas from women infected
with SARS-CoV-2 in their cohort indicated a higher incidence of decidual
arteriopathy (47% vs 16%; P¼.04),
delayed villous maturation (27% vs 4%;
P<.001), chorangiosis (27% vs 5%;
P¼.001), and intervillous thrombi (40%
vs 9%; P<.001).25 The rates of delayed
villous maturation, chorangiosis, and
intervillous thrombi were lower in our
cohort of placentas from pregnancies
with SARS-CoV-2 infection, and
decidual vasculopathy was not seen in
any case. Baergen and Heller26 have also
recently reported placental ﬁndings
from 20 cases of third-trimester
maternal
SARS-CoV-2
infection
without a comparative group. With a
gestational age range of cases from 32 2/
7 to 40 4/7 weeks, including 1 twin
pregnancy, they found incidences of
low-grade fetal vascular malperfusion
and maternal vascular malperfusion in
45% and 20% of cases, respectively.26
Although disease severity based on the
established criteria was not reported in
either study by Shanes et al25 and
Baergen and Heller,26 the incidence of

Other or multiracial

2 (12.5)

4 (11.8)

Unknown

0 (0)

2 (5.8)

Nulliparous, n (%)
Gestational age at delivery (wk),
median (IQR)

7 (43.8)
39.1 (38.38e40.00)

Time interval from diagnosis of
12.5 (8.25e20.00)
infection to delivery (d), median (IQR)

19 (55.9)

.55

39.3 (38.75e40.38) .22
0.5 (0e1)

<.001

Antepartum or intrapartum
complications, n (%)
Pregestational diabetes

1 (6.2)

0

Gestational diabetes

0

1 (2.9)

1

Gestational hypertension

0

3 (8.8)

.54

Preeclampsia with severe features

1 (6.2)

3 (8.8)

1

Preeclampsia without severe
features

1 (6.2)

0

Fetal growth restriction

0

2 (5.9)

1

Intrahepatic cholestasis of
pregnancy

1 (6.2)

2 (5.9)

1

Oligohydramnios

1 (6.2)

0

Intrapartum fever

2 (12.5)

6 (17.6)

1

Vaginal delivery, n (%)

10 (62.5)

28 (82.4)

.16

Birthweight (g), median (IQR)

3180 (2699e3421)

3235 (2775e3450)

.32

.32

.32

.44

Data are presented as number (percentage) or median (IQR).
IQR, interquartile range; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Gulersen et al. Placental histopathologic changes after maternal SARS-CoV-2 infection. AJOG MFM 2020.

cases without symptoms associated
with the infection varied between
33.3% and 85%, respectively. Differences in case sample size, the nature of
case selection, the rate of cases with
symptoms related to infection, the
severity of symptoms, the incidence of
adverse pregnancy outcomes, variations
in the degree of diversity in patient
populations,
and
interobserver

variability may have contributed to
the differences in the placental ﬁndings
reported by Shanes et al25 and Baergen
and Heller26 compared with our study.

Clinical implications
The typical course of SARS-CoV-2
infection and its clinical sequelae in
humans is still being studied. Early reports have suggested an incubation
NOVEMBER 2020 AJOG MFM
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TABLE 4

Comparison of histopathologic characteristics between placentas from
women after diagnosis of SARS-CoV-2 infection who had typical symptoms
related to the infection and those without such typical symptoms

Histopathologic characteristic

Patients with
symptoms related
to SARS-CoV-2
infection (n¼16)

Patients without
symptoms related
to SARS-CoV-2
infection (n¼34)

P value

Placental weight
<10th percentile
10the90th percentile
>90th percentile

1 (6.2)

6 (17.6)

13 (81.2)

27 (79.4)

2 (12.5)

.32

1 (2.9)

Maternal vascular malperfusion
Distal villous hypoplasia

0

Excessive infarction

3 (18.8)

Old hemorrhage in membranes

1 (6.2)

2 (5.9)

1

1 (2.9)

.09

0

.32

Fetal vascular malperfusion

1 (6.2)

3 (8.8)

1

Increased perivillous fibrin

2 (12.5)

4 (11.8)

1

Intervillous thrombus

6 (37.5)

7 (20.6)

.3

Delayed villous maturation

2 (12.5)

8 (23.5)

.47

2 (5.9)

1

Villitis

0

Chorionitis

2 (12.5)

9 (26.5)

.47

Amnionitis

2 (12.5)

7 (20.6)

.7

Umbilical vasculitis

2 (12.5)

5 (14.7)

1

Retroplacental thrombus

2 (12.5)

0

.1

Chorangiosis

1 (6.2)

2 (5.9)

1

Meconium staining

4 (25)

5 (14.7)

.44

Data are presented as number (percentage).
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Gulersen et al. Placental histopathologic changes after maternal SARS-CoV-2 infection. AJOG MFM 2020.

period of up to 14 days, with a median
time of 4 to 5 days from exposure to
symptom onset.33e35 The illness severity
ranges from asymptomatic carriers to
critical with respiratory failure, shock, or
multiorgan system dysfunction.32e35
However, not all patients infected with
the virus exhibit typical symptoms
related to the infection, and the physiological effect of this presentation in
pregnant women is unknown. Given the
varying clinical presentations of infection, it is reasonable to consider that
histopathologic changes in organs such
as the placenta may result as a direct
insult from the infection, or indirectly
from maternal physiological changes.
Whether this may impact antenatal
6 AJOG MFM NOVEMBER 2020

surveillance remains to be seen. The results of this study suggest that pregnancy
with maternal SARS-CoV-2 infection
may be managed based on the clinical
ﬁndings alone, because ﬁndings from
placental
pathology
warranting
increased or different surveillance were
not indicated.
A particular point of interest
regarding the physiological response to
SARS-CoV-2 infection has been its
associated prothrombotic state.36,37
Thus far, evidence has not proven that
pregnant women with infection are
more likely to suffer from venous
thromboembolism. On a recent evaluation by Mulvey et al27 of 5 term placentas
from women with SARS-CoV-2

infection who were classiﬁed as mostly
without typical symptoms related to
infection, all 5 indicated evidence of fetal
vascular malperfusion with thrombosis.
The rate of fetal vascular malperfusion in
our study was relatively low and was
similar in patients who presented with
and without typical symptoms related to
the infection. This was despite a signiﬁcant difference in the time interval from
the diagnosis of infection to delivery,
which likely reﬂects the universal testing
performed on women admitted for delivery at our institution. Whether such
histopathologic ﬁndings were related to
the time interval from infection to delivery or were a result of maternal
immunologic response to infection requires further study, including identifying possible associated markers on a
molecular level.

Research implications
Data regarding SARS-CoV-2 and its
impact on pregnancy are rapidly
evolving. To date, it remains unclear if
vertical transmission—either intrauterine, intrapartum, or immediately postpartum—of SARS-CoV-2 occurs.13e17
Further evidence concluding whether
SARS-CoV-2 can infect the placenta,
traverse the placental barrier or induce
morphologic changes is needed. Reports
have suggested that cell entry of SARSCoV-2 is mediated through the
angiotensin-converting
enzyme
2
(ACE2) receptor.38 Although ACE2
expression has been reported at the
maternal-fetal interface of placentas,39
the correlation between receptor
expression, viral load, and associated
histologic changes has not been studied.
Our ﬁndings of no signiﬁcant difference
in placental histopathology after the
third-trimester diagnosis of SARS-CoV2 infection are reassuring. However, in
the absence of placental SARS-CoV-2
testing and standardized serology
testing for neonates, we cannot assume
or refute vertical transmission. Furthermore, whether these pathologic ﬁndings
would be similar after ﬁrst or secondtrimester SARS-CoV-2 infection and
whether earlier infection increases the
likelihood of vertical transmission is
unknown and requires further study.

Original Research
Strengths and limitations
There are several strengths to this study.
This study reported a cohort of examined placentas from pregnancies with
SARS-CoV-2 infection and the comparison of histopathologic ﬁndings in
women with and without symptoms
related to infection. Our control group
was matched by gestational age and had
the same median maternal age; thus,
there were limited possible confounders.
Our population was diversiﬁed in terms
of demographics and was derived from
New York, where the total number of
novel coronavirus infections is among
the highest worldwide. Finally, all placentas were reviewed by only 1 pathologist subsequent to the initial
histopathologic examination, which
reduced the impact of interobserver
variability.
There are also several limitations to
this study. The pathologist was not
blinded to the clinical history or status of
SARS-CoV-2 infection for each placenta
examined, which may have introduced
bias regarding interpretation. However,
this is unlikely because no pattern of
signiﬁcant histopathologic changes were
found. Despite a larger sample size of
cases relative to other reports in the
literature, several outcomes had relatively low frequencies. This may have
limited the power to detect signiﬁcant
differences, particularly when histopathologic characteristics in placentas
from infected patients with or without
symptoms related to SARS-CoV-2
infection were compared. We also utilized a historical control group with
several clinical diagnoses that may have
contributed to the abnormal pathologic
ﬁndings, because placentas are not
routinely sent for examination at our
institution. However, the rates of these
diagnoses were similar between cases
from infected pregnancies and controls.
We did not test each placenta for the
presence of SARS-CoV-2. Nevertheless,
the test results of all neonates at 24 hours
of life were negative for infection. The
results of this study are only reﬂective of
the third trimester SARS-CoV-2 infection. Whether signiﬁcant placental histopathologic changes occur after the ﬁrst

or second-trimester infection is unknown. Finally, it is unknown whether
our reported ﬁndings are directly related
to placental infection or an indirect effect
from maternal physiological or immune
response to infection.

Conclusions
The results of this study add to the
limited existing literature focused on
placental histopathologic changes associated with SARS-CoV-2 infection and
suggest that there is no increased risk of
signiﬁcant placental histopathologic
changes that occur after the diagnosis of
SARS-CoV-2 in the third trimester
regardless of the presence or absence of
symptoms typically related to infection.
Future studies examining histopathologic changes associated with earlier
infection and identifying key placental
biological markers on a molecular level
that may be directly affected by SARSCoV-2 are needed to better understand
the impact of this virus on placental
physiology.
n
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